Gilead Sciences

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

News

Gilead looks beyond Trodelvy with Tubulis alliance

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.

News

Kelun's MSD-partnered TROP2 drug gets first okay in China

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

Gilead, MSD say HIV combo could be weekly, oral HIV drug

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients

FDA sets June date for Gilead's twice-yearly HIV PrEP

Galapagos unveils plan to split, hiving off its drugs unit

ICER identifies new crop of 'unsupported' drug price rises

Gilead looks beyond Trodelvy with Tubulis alliance

Kelun's MSD-partnered TROP2 drug gets first okay in China

Gilead, MSD say HIV combo could be weekly, oral HIV drug

Moderna jab on trial for cancer-causing syndrome

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks